Skip to content
AwardedSpainGoods€201,353

Suministro de los principios activos denominados "Faricimab 28,8 MG / 0,24 ML VIAL 0,24 ML Intravitrea" Y "Polatuzumab Vedotina 30MG POLVO PERFUSION".

Published
Published 10 March 2025

Overview

The Hospital Universitario de Gran Canaria Doctor Negrín procured the active pharmaceutical ingredients Faricimab 28.8 mg/0.24 ml intravitreal vial and Polatuzumab Vedotina 30 mg infusion powder, classified as miscellaneous medicines. The contract was awarded to Roche Farma, S.A. on 22 January 2025 for a total value of €487,706.10.

Key details

Country
Spain
Status
Awarded
Category
Goods
Estimated value
€201,353
Procedure
Direct
Published
10 March 2025
Classification (CPV)
Various medicinal products

Award outcome

Awarded value
€487,706
Award date
22 January 2025
Winner
  • Roche Farma, S.A.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    10 March 2025

Contracting authority

  • Dirección Gerencia Hospital Universitario de Gran Canaria Doctor Negrín

    Procuring entity

    Las Palmas de Gran Canaria, Spain

    ID_PLATAFORMA: 21050930148853

    Authority website ↗

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Suministro de los principios activos denominados "Faricimab 28,8 MG / 0,24 ML VIAL 0,24 ML Intravitrea" Y "Polatuzumab Vedotina 30MG POLVO PERFUSION". — won by Roche Farma, S.A. — Skim